ONXX..$45.40 up over 3% or $1.51. Nice move after disappointing lung cancer trials. Message in reply to: ONXX..$42.90 Phase III MISSION trial of Nexavar in Patients with NSCLC Did Not Meet Primary Endpoint. http://yhoo.it/KGJw65